| 标题： | 中国可切除食管癌围术期诊疗指南（2022年） |
| title： | Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2022) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 从事食管癌围术期诊疗管理的各级医务工作者。 |
| Guide users： | Healthcare personnel at all levels involved in the perioperative management of esophageal cancer. |
| 证据分级方法： | 此项基于系统性回顾分析的临床指南由包括中国国家癌症中心撰写委员会成员的多学科专家组完成，后者负责全面性文献检索并且基于文献回顾制定诊疗推荐内容。专家组成员之间通过当面沟通、电话或网络视频会议，以及电子邮件形式交流。鉴于循证医学评估需要，所有成员均受邀为指南制定提供智力支持、专业评判，并且最终完成撰写指南推荐内容。专家组成员负责在投稿发表前完成初稿，并且在成员范围内传阅审校。 中国医师协会胸外科医师分会食管外科专委会委员，中华医学会胸心血管外科分会食管疾病学组成员及国际食管疾病学会中国分会会员共同参与评价多学科专家组拟定的指南推荐内容，权衡风险与获益，并且对推荐项目进行评级。按计划召开涉及此指南制定主题的线上或线下会议，以多轮投票方式正式达成共识。所有指南推荐均需经过投票达到75%以上的共识率。 每项循证医学证据水平评估均应用Cochrane偏倚风险工具以及GRADE质量评估标准辅助形成指南推荐。GRADE质量评估分级（例如，高、中、低、极低）由方法学家协同多学科专家组评定。 |
| Evidence grading method： | This systematic review–based guideline was developed by a multidisciplinary Expert Panel that included the NCC writing committee members, who performed comprehensive literature searches and developed recommendations based on the literature review. The Expert Panel had one in-person meeting, conducted other meetings via teleconference and/or webinar, and corresponded through e-mail. Based on the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. Members of the Expert Panel were responsible for reviewing and approving the penultimate version of the guideline, which was then circulated for open comment before submission for editorial review and consideration for publication. The CATS Esophageal Surgery Committee members, CSTCVS Esophageal Disease Panelists and CSDE members graded the evidence supporting the recommendations and assessed the risk-benefit profile for each recommendation. A scheduled teleconference was used to organize the topics covered by the guideline and review the proposed recommendations, and subsequent teleconferences were then held to vote on the final recommendations formally. Acceptance for the final recommendations required greater than 75% approval of each of the recommendations. Certainty of the evidence (i.e., evidence quality) for each outcome was assessed using the Cochrane Risk of Bias tool and elements of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) quality assessment and recommendations development process. GRADE quality assessment labels (i.e., high, moderate, low, very low) were assigned for each outcome by the project methodologist in collaboration with the Expert Panel co-chairs and reviewed by the full Expert Panel. |
| 制定单位： | 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院；中国医师协会胸外科医师分会；中华医学会胸心血管外科学分会；国际食管疾病学会中国分会 |
| Formulating unit： | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College; Chinese Association of Thoracic Surgeons; Chinese Society for Thoracic and Cardiovascular Surgery; Chinese Society for Diseases of the Esophagus |
| 注册时间： | 2022-07-03 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN377 |
| Registration number： | |
| 指南制订的目的： | 食管癌及食管胃交界部癌是公认的高侵袭性恶性肿瘤之一，严重危害人类健康，尤其我国广大人民群众。当前尚缺乏关于可手术的食管癌最佳诊疗实践的国际专家共识。为了制定一项基于循证医学证据的临床实践指导以辅助临床决策，由中国国家癌症中心、中国医师协会、中华医学会胸心血管外科学分会及国际食管疾病学会中国分会共同组织专家小组对近年来已发表的关于可切除的食管癌患者围术期管理的文献进行系统性回顾分析，并且对此类患者提供诊疗推荐。 |
| Purpose of the guideline： | Esophagogastric cancer is an aggressive tumor with a significant global burden, especially in China. There is no international consensus on the optimal management of resectable esophageal cancer. To develop an evidence-based clinical practice guideline to assist in clinical decision-making, the Chinese National Cancer Center (NCC), Chinese Association of Thoracic Surgeons (CATS), Chinese Society for Thoracic and Cardiovascular Surgery (CSTCVS), and Chinese Society for Diseases of the Esophagus (CSDE) jointly convened an Expert Panel to conduct a systematic review of the more recently published literature (2000-2022) on perioperative management options for patients with resectable esophageal cancer and provide recommended care options for this patient population. |
